GlobalData on MSN
CatalYm doses first patient in Phase II/III VINCIT trial
The trial plans to enrol approximately 518 participants.
1d
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed
CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia ...
In a recent study published in Nature Communications, researchers evaluate the impact of tumor-derived growth and differentiation factor-15 (GDF-15) on leukocyte function-associated antigen 1 ...
MUNICH, April 25, 2025--(BUSINESS WIRE)--CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage antibody visugromab can improve the anti ...
Levels of growth differentiation factor-15 (GDF-15), a biomarker of oxidative stress and inflammation, are significantly associated with short-term adverse outcomes among adults presenting to the ...
The vampiric exchange of young blood and old blood has long been reported to have anti-aging effects has been to linked GDF-11 but an analysis of how GDF-11 works in the muscles found just the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results